682 related articles for article (PubMed ID: 19543061)
1. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
[TBL] [Abstract][Full Text] [Related]
3. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis.
Tanriover B; Wright SE; Foster SV; Roush KS; Castillo-Lugo JA; Fa K; Levy FL; Mejia A
Transplant Proc; 2008 Dec; 40(10):3393-6. PubMed ID: 19100397
[TBL] [Abstract][Full Text] [Related]
4. Impact of rituximab therapy for treatment of acute humoral rejection.
Kaposztas Z; Podder H; Mauiyyedi S; Illoh O; Kerman R; Reyes M; Pollard V; Kahan BD
Clin Transplant; 2009; 23(1):63-73. PubMed ID: 19200217
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
6. Antibody-mediated rejection: treatment alternatives and outcomes.
Singh N; Pirsch J; Samaniego M
Transplant Rev (Orlando); 2009 Jan; 23(1):34-46. PubMed ID: 19027615
[TBL] [Abstract][Full Text] [Related]
7. Current approaches to treatment of antibody-mediated rejection.
Jordan SC; Vo AA; Tyan D; Nast CC; Toyoda M
Pediatr Transplant; 2005 Jun; 9(3):408-15. PubMed ID: 15910400
[TBL] [Abstract][Full Text] [Related]
8. Experience with antibody-mediated rejection in kidney allograft recipients.
Wade E; Goral S; Kearns J; Pierce E; Trofe J; Bloom R; Kamoun M
Clin Transpl; 2006; ():439-46. PubMed ID: 18365401
[TBL] [Abstract][Full Text] [Related]
9. Therapy with plasmapheresis and intravenous immunoglobulin for acute humoral rejection in kidney transplantation.
Ibernón M; Gil-Vernet S; Carrera M; Serón D; Moreso F; Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3743-5. PubMed ID: 16386524
[TBL] [Abstract][Full Text] [Related]
10. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
11. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
12. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
13. Characterization of rejection episodes in patients following positive crossmatch and ABO-incompatible live donor renal transplantation.
Kayler LK; Farber JL; Colombe B; LaCava D; Friedewald JJ; Ratner LE
Transpl Int; 2006 Feb; 19(2):128-39. PubMed ID: 16441362
[TBL] [Abstract][Full Text] [Related]
14. Novelties in diagnostics and therapy of antibody mediated rejection.
Dragun D; Rudolph B
Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii50-viii53. PubMed ID: 17890264
[TBL] [Abstract][Full Text] [Related]
15. Alloantibodies and the outcome of cadaver kidney allografts.
Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N
Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection.
Hong YA; Kim HG; Choi SR; Sun IO; Park HS; Chung BH; Choi BS; Park CW; Kim YS; Yang CW
Transplant Proc; 2012 Jan; 44(1):182-4. PubMed ID: 22310610
[TBL] [Abstract][Full Text] [Related]
17. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.
Slatinska J; Honsova E; Burgelova M; Slavcev A; Viklicky O
Ther Apher Dial; 2009 Apr; 13(2):108-12. PubMed ID: 19379149
[TBL] [Abstract][Full Text] [Related]
18. Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report.
Celik A; Saglam F; Cavdar C; Sifil A; Atila K; Sarioglu S; Bora S; Gulay H; Camsari T
Transplant Proc; 2008; 40(1):302-4. PubMed ID: 18261611
[TBL] [Abstract][Full Text] [Related]
19. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up.
Billing H; Rieger S; Süsal C; Waldherr R; Opelz G; Wühl E; Tönshoff B
Transpl Int; 2012 Nov; 25(11):1165-73. PubMed ID: 22897111
[TBL] [Abstract][Full Text] [Related]
20. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]